期刊文献+

表皮生长因子受体在老年大肠癌中的表达及临床意义

Expression of epidermal growth factor receptor in geriatric large intestine carcinoma and its clinical significance
下载PDF
导出
摘要 目的探讨表皮生长因子受体(EGFR)在老年大肠癌组织中的表达及其临床意义。方法采用免疫组化SABC法对87例大肠癌、14例大肠炎性黏膜和26例大肠腺瘤样息肉进行检测。结果EGFR在大肠炎性黏膜、腺瘤样息肉和大肠癌中阳性率分别为21.43%、46.15%和54.02%,其中EGFR在炎性黏膜中表达率明显低于腺瘤样息肉和大肠癌(P<0.05);EGFR表达与大肠癌浸润深度和淋巴结转移有相关性(P<0.05)。结论EGFR过度表达,在老年大肠癌的发生过程中可能起重要作用;检测EGFR对于指导临床治疗和判断预后有重要意义。 Objective To study the expression of epidermal growth factor receptor (EGFR) in geriatric large intestine carcinoma and its clinical significance. Methods Immunohistochemical method (SABC) was used to detect the expression of EGFR in 87 large intestino careinoma tissues, 14 mucesitis tissues and 26 polypoid adenoma tissues. ResultS The positive rates of EGFR in mucesitis, polypoid adenoma and large intestine carcinoma were 21.43%, 46. 15% and 54. 02%. The expression rates in mucesitis were significantly lower than that in polypcdd adenoma and large intestine carcinoma (P 〈 0. 05). The expression of EGFR in large intestine carcinoma was related to invasion depth and lymph node metastasis ( P 〈 0. 05 ). Conclusions The over-expression of EGFR may play important roles in the geriatric large intestine carcinoma. The expression of EGFR in the cancer could play a certain role in judging prognosis and guiding clinical treatment.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2006年第12期1660-1661,共2页 Chinese Journal of Gerontology
基金 河北省科技攻关项目(03276117)
关键词 大肠癌 表皮生长因子受体 炎性黏膜 腺瘤样息肉 免疫组织化学 Large intestine carcinoma Epldennal growth factor receptor (EGFR) Mucositis Polypoid adenoma Immunohistochemlarry
  • 相关文献

参考文献7

  • 1胡庆军,史朝晖.EGFR和PCNA在食管癌中的表达及其临床意义[J].山东医药,2005,45(5):42-43. 被引量:3
  • 2张宇春,杨纯正.针对EGFR靶点的肿瘤治疗[J].国外医学(肿瘤学分册),2004,31(5):359-361. 被引量:10
  • 3Liu VW,Grandis JR.EGFR mediated cell cycle regualation[J].Anticancer Res,2002 ;22:1-10.
  • 4Jorissen RN,Walker F,Pouliot N,et al.Epidermal growth foetor receptor:mechanisms of activation and signaling[J].Exp cell Res,2003 ;284:31-40.
  • 5Kopp R,Rothbauer E,Ruge M,et al.Clinical implications of the EGF receptor/ligand system for tamor progression and survival in gastrointestinal carcinomas:evidence for new therapeutic options[J].Recent Results Cancer Res,2003; 162:115-123.
  • 6Kruger JS,Redoly KB.Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-over expressing cells[J].Mol Cancer Res,2003; 1 (11):801-12.
  • 7任晓岚,汪鑫,李志裕,尤启冬.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的研究进展[J].中国新药杂志,2005,14(7):821-826. 被引量:31

二级参考文献54

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量:9
  • 2栾复新,王孟薇,祝庆孚,尤纬缔.幽门螺杆菌感染与PCNA、TGF-α、EGFR表达关系的探讨[J].临床消化病杂志,1996,8(4):148-150. 被引量:13
  • 3Shou W,Gregory JH,David B,et al.The p21 inhibitor of cyclin-dependent kinases control DNA replication by interaction with PCNA.Nature,1994,369(16):574~578.
  • 4Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpessing breast cancer cell line proliferation, radiosensitization, and resistance [ J ]. Int J Radiat Oncol Biol Phys ,2004,58(2):344- 352.
  • 5Smaill JB,Hollis HD,Zhou H, et al. Tyrosine kinase inhibitors. 18.6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor[J]. J Med Chem ,2001,44(3) :429 - 440.
  • 6David WF, Alexander JB, William AD, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor[J]. Proc Natl Acad Sci USA,1998,95(9) : 12022 - 12027.
  • 7Tsou HR, Mamuya N, Johnson BD, et al. 6-substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity[J]. J Med Chem .2001.44(17) :2719-2734
  • 8Liechti C,Sequin U, Bold G, et al. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor [ J ]. Eur J Med Chem ,2004,39( 1 ) : 11 - 26.
  • 9Dancey J. Epidermal growth factor receptor inhibitors in clinical development[J]. Int J Radiat Oncol Biol Phys ,2004,58(3) : 1003 -1007.
  • 10Michael AG, Bock C, Ferguson LR. Evidence for epidermal growth factor receptorenhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033 [J].Anticancer Drugs ,2001,12(7) :683 - 690.

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部